NewAmsterdam Pharma Company NV - Warrants (15/11/2027)
NAMSW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.11B
Close$
$3.05
66.1% downside
Current Fair Value
66.1% downsideOvervalued by 66.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.11 Billion |
|---|---|
| Enterprise Value | $687.15 Million |
| Earnings per Share | $-1.75 |
| Beta | 0.11 |
| Outstanding Shares | 123,370,232 |
Return
| Return on Equity | -41.10% |
|---|---|
| Return on Assets | -36.84% |
| Return on Invested Capital | -40.57% |
Valuation & Multiples
| P/E Ratio | -9.2 |
|---|---|
| PEG | -3.42 |
| Price to Sales | - |
| Price to Book Ratio | 1.8 |
| Enterprise Value to Revenue | 96.5 |
| Enterprise Value to EBIT | -2.68 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.47
Consensus analyst estimateRevenue Estimate
$1.88 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.49
Consensus analyst estimateRevenue Estimate
$7.54 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.